Dapirolizumab Pegol Shows Promise in Systemic Lupus Erythematosus Management
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Significant Disease Control: The Phase 3 PHOENYCS GO study demonstrated that dapirolizumab pegol combined with standard care achieved sustained disease control at lower glucocorticoid doses through Week 48, indicating its potential to reduce long-term steroid use and associated side effects for patients.
- Immunological Marker Improvements: Findings presented at EULAR 2026 revealed significant improvements in anti-dsDNA antibodies and complement proteins C3 and C4 in patients treated with dapirolizumab pegol, highlighting its effectiveness in alleviating symptoms of systemic lupus erythematosus (SLE).
- Reduced Flare Rates: The study indicated that patients receiving dapirolizumab pegol experienced significantly lower rates of moderate or severe BILAG-2004 flares through Week 48 compared to the placebo group, suggesting its advantages in controlling disease activity and potentially enhancing patients' quality of life.
- Clinical Collaboration Prospects: The partnership between UCB and Biogen further advances the clinical development of dapirolizumab pegol, which is expected to provide more effective treatment options for SLE patients, addressing the urgent market demand for new therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UCB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UCB
Wall Street analysts forecast UCB stock price to rise
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 32.880
Low
34.00
Averages
114.43
High
349.72
Current: 32.880
Low
34.00
Averages
114.43
High
349.72
About UCB
United Community Banks, Inc. is the financial holding company for United Community (the Bank). The Bank offers a full range of banking, mortgage and wealth management services. The Bank operates approximately 200 offices across Alabama, Florida, Georgia, North Carolina, South Carolina and Tennessee. It also manages a national SBA lending franchise and a national equipment finance subsidiary, extending its reach to businesses across the country. It provides a range of financial products and services to the commercial, retail, governmental, educational, energy, healthcare and real estate sectors. This includes a variety of deposit products, secured and unsecured loans, mortgage loans, payment and commerce solutions, equipment finance services, wealth management, trust services, private banking, investment advisory services, insurance services, and other related financial services. These products and services are delivered through a variety of channels.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dapirolizumab Pegol Shows Promise in Systemic Lupus Erythematosus Management
- Significant Disease Control: The Phase 3 PHOENYCS GO study demonstrated that dapirolizumab pegol combined with standard care achieved sustained disease control at lower glucocorticoid doses through Week 48, indicating its potential to reduce long-term steroid use and associated side effects for patients.
- Immunological Marker Improvements: Findings presented at EULAR 2026 revealed significant improvements in anti-dsDNA antibodies and complement proteins C3 and C4 in patients treated with dapirolizumab pegol, highlighting its effectiveness in alleviating symptoms of systemic lupus erythematosus (SLE).
- Reduced Flare Rates: The study indicated that patients receiving dapirolizumab pegol experienced significantly lower rates of moderate or severe BILAG-2004 flares through Week 48 compared to the placebo group, suggesting its advantages in controlling disease activity and potentially enhancing patients' quality of life.
- Clinical Collaboration Prospects: The partnership between UCB and Biogen further advances the clinical development of dapirolizumab pegol, which is expected to provide more effective treatment options for SLE patients, addressing the urgent market demand for new therapies.
See More
Dapirolizumab Pegol Clinical Trial Shows Significant Results
- Clinical Trial Results: In the PHOENYCS GO study, 50% of patients receiving dapirolizumab pegol plus standard of care achieved a BICLA response at Week 48, significantly higher than the 35% in the placebo group, indicating its potential in treating systemic lupus erythematosus (SLE).
- Multiple Endpoint Improvements: The study demonstrated that dapirolizumab pegol outperformed placebo across various disease activity measures, including severe BILAG flares, SLEDAI-2K scores, and patient-reported fatigue, highlighting its positive impact on patient quality of life.
- Glucocorticoid Sparing Effect: At Week 48, a greater proportion of patients in the dapirolizumab pegol group were able to reduce their glucocorticoid dose from >7.5 mg/day to ≤7.5 mg/day, suggesting a glucocorticoid-sparing effect that aligns with treatment guidelines.
- Favorable Safety Profile: The safety profile of dapirolizumab pegol was consistent with previous studies, with treatment-emergent adverse events occurring in 82.6% of patients, yet serious adverse events were lower at 10.0%, indicating its acceptability in clinical use.
See More
Investment Risk Analysis of United Community Banks
- Weak Revenue Growth: United Community Banks has reported a mediocre annualized revenue growth of 9.5% over the past five years, which falls short of the banking sector benchmark, indicating potential challenges in sustaining future profitability.
- Slow EPS Growth: The bank's earnings per share (EPS) have only grown at a compounded annual growth rate of 3.5% over the last five years, which is lower than its revenue growth, suggesting a decline in profitability per share as the company expanded, raising concerns for investors.
- Limited TBVPS Growth: Consensus estimates project that United Community Banks' tangible book value per share (TBVPS) will grow by a mere 8% to $24.27 over the next 12 months, a growth rate deemed insufficient to attract investors looking for robust returns.
- Cautious Investment Recommendation: While the bank's current valuation at $32.06 per share is considered fair, the limited upside compared to potential downside risks suggests that investors may prefer to seek more attractive investment opportunities elsewhere.
See More
United Community Banks Declares Quarterly Dividend of $0.25
- Quarterly Dividend Declaration: United Community Banks has declared a quarterly dividend of $0.25 per share, consistent with previous distributions, indicating the company's stable cash flow and shareholder return strategy, which is expected to bolster investor confidence.
- Dividend Yield: The forward yield of 3.06% reflects the company's attractiveness in the current market environment, potentially drawing in more investors seeking stable income.
- Payment Schedule: The dividend will be payable on July 3, with a record date of June 15 and an ex-dividend date also on June 15, ensuring shareholders receive timely returns and further solidifying shareholder relations.
- Future Outlook: United Community Banks anticipates a 3-5 basis point expansion in net interest margin for Q2 while outlining a 40% cost savings in the Peach State deal, demonstrating proactive measures in business expansion and profitability enhancement.
See More
United Community Banks Acquires Candel Therapeutics for $2.2 Billion
- Acquisition Scale: United Community Banks has agreed to acquire Candel Therapeutics for up to $2.2 billion, with $2 billion paid upfront and an additional $200 million contingent on future milestones, aimed at strengthening its pipeline for immune-related disease treatments.
- Expected Timeline: The deal is anticipated to close between late Q2 and early Q3 of 2026, reflecting UCB's confidence and strategic positioning in the future biologics sector.
- Manageable Financial Impact: UCB stated that the financial impact of the acquisition will be manageable, with its 2026 outlook remaining unchanged, projecting steady revenue and profit growth, indicating a positive outlook for future development.
- Candel's Drug Progress: Candel's main drug, cizutamig, is currently undergoing several Phase 1 clinical trials aimed at helping the immune system target harmful cells, further enhancing UCB's innovative capabilities in the biopharmaceutical field.
See More
Three Stocks to Watch Under $50
- UCB's Growth Concerns: United Community Banks (UCB) has shown only 7.6% annual revenue growth over the past two years, which is below banking sector standards, indicating potential risks to profitability that could affect investor confidence.
- SLM's Market Challenges: Sallie Mae (SLM) has experienced flat sales over the past two years, with an annual EPS growth of only 3.1%, significantly trailing the peer group average, reflecting a lack of competitiveness in its products and services during the current market cycle.
- NRDS's Strong Performance: NerdWallet (NRDS) achieved an impressive 27.8% annual revenue growth over the past five years, and its stock buybacks propelled EPS growth to 252%, showcasing its robust competitive position and profitability in the market.
- Investment Opportunity Analysis: In the current market environment, UCB and SLM present concerning performance metrics, while NRDS demonstrates strong growth potential, prompting investors to carefully assess the investment value of these stocks.
See More
Dapirolizumab Pegol Shows Promise in Systemic Lupus Erythematosus Management
- Significant Disease Control: The Phase 3 PHOENYCS GO study demonstrated that dapirolizumab pegol combined with standard care achieved sustained disease control at lower glucocorticoid doses through Week 48, indicating its potential to reduce long-term steroid use and associated side effects for patients.
- Immunological Marker Improvements: Findings presented at EULAR 2026 revealed significant improvements in anti-dsDNA antibodies and complement proteins C3 and C4 in patients treated with dapirolizumab pegol, highlighting its effectiveness in alleviating symptoms of systemic lupus erythematosus (SLE).
- Reduced Flare Rates: The study indicated that patients receiving dapirolizumab pegol experienced significantly lower rates of moderate or severe BILAG-2004 flares through Week 48 compared to the placebo group, suggesting its advantages in controlling disease activity and potentially enhancing patients' quality of life.
- Clinical Collaboration Prospects: The partnership between UCB and Biogen further advances the clinical development of dapirolizumab pegol, which is expected to provide more effective treatment options for SLE patients, addressing the urgent market demand for new therapies.
See More
Dapirolizumab Pegol Clinical Trial Shows Significant Results
- Clinical Trial Results: In the PHOENYCS GO study, 50% of patients receiving dapirolizumab pegol plus standard of care achieved a BICLA response at Week 48, significantly higher than the 35% in the placebo group, indicating its potential in treating systemic lupus erythematosus (SLE).
- Multiple Endpoint Improvements: The study demonstrated that dapirolizumab pegol outperformed placebo across various disease activity measures, including severe BILAG flares, SLEDAI-2K scores, and patient-reported fatigue, highlighting its positive impact on patient quality of life.
- Glucocorticoid Sparing Effect: At Week 48, a greater proportion of patients in the dapirolizumab pegol group were able to reduce their glucocorticoid dose from >7.5 mg/day to ≤7.5 mg/day, suggesting a glucocorticoid-sparing effect that aligns with treatment guidelines.
- Favorable Safety Profile: The safety profile of dapirolizumab pegol was consistent with previous studies, with treatment-emergent adverse events occurring in 82.6% of patients, yet serious adverse events were lower at 10.0%, indicating its acceptability in clinical use.
See More
Investment Risk Analysis of United Community Banks
- Weak Revenue Growth: United Community Banks has reported a mediocre annualized revenue growth of 9.5% over the past five years, which falls short of the banking sector benchmark, indicating potential challenges in sustaining future profitability.
- Slow EPS Growth: The bank's earnings per share (EPS) have only grown at a compounded annual growth rate of 3.5% over the last five years, which is lower than its revenue growth, suggesting a decline in profitability per share as the company expanded, raising concerns for investors.
- Limited TBVPS Growth: Consensus estimates project that United Community Banks' tangible book value per share (TBVPS) will grow by a mere 8% to $24.27 over the next 12 months, a growth rate deemed insufficient to attract investors looking for robust returns.
- Cautious Investment Recommendation: While the bank's current valuation at $32.06 per share is considered fair, the limited upside compared to potential downside risks suggests that investors may prefer to seek more attractive investment opportunities elsewhere.
See More
United Community Banks Declares Quarterly Dividend of $0.25
- Quarterly Dividend Declaration: United Community Banks has declared a quarterly dividend of $0.25 per share, consistent with previous distributions, indicating the company's stable cash flow and shareholder return strategy, which is expected to bolster investor confidence.
- Dividend Yield: The forward yield of 3.06% reflects the company's attractiveness in the current market environment, potentially drawing in more investors seeking stable income.
- Payment Schedule: The dividend will be payable on July 3, with a record date of June 15 and an ex-dividend date also on June 15, ensuring shareholders receive timely returns and further solidifying shareholder relations.
- Future Outlook: United Community Banks anticipates a 3-5 basis point expansion in net interest margin for Q2 while outlining a 40% cost savings in the Peach State deal, demonstrating proactive measures in business expansion and profitability enhancement.
See More
United Community Banks Acquires Candel Therapeutics for $2.2 Billion
- Acquisition Scale: United Community Banks has agreed to acquire Candel Therapeutics for up to $2.2 billion, with $2 billion paid upfront and an additional $200 million contingent on future milestones, aimed at strengthening its pipeline for immune-related disease treatments.
- Expected Timeline: The deal is anticipated to close between late Q2 and early Q3 of 2026, reflecting UCB's confidence and strategic positioning in the future biologics sector.
- Manageable Financial Impact: UCB stated that the financial impact of the acquisition will be manageable, with its 2026 outlook remaining unchanged, projecting steady revenue and profit growth, indicating a positive outlook for future development.
- Candel's Drug Progress: Candel's main drug, cizutamig, is currently undergoing several Phase 1 clinical trials aimed at helping the immune system target harmful cells, further enhancing UCB's innovative capabilities in the biopharmaceutical field.
See More
Three Stocks to Watch Under $50
- UCB's Growth Concerns: United Community Banks (UCB) has shown only 7.6% annual revenue growth over the past two years, which is below banking sector standards, indicating potential risks to profitability that could affect investor confidence.
- SLM's Market Challenges: Sallie Mae (SLM) has experienced flat sales over the past two years, with an annual EPS growth of only 3.1%, significantly trailing the peer group average, reflecting a lack of competitiveness in its products and services during the current market cycle.
- NRDS's Strong Performance: NerdWallet (NRDS) achieved an impressive 27.8% annual revenue growth over the past five years, and its stock buybacks propelled EPS growth to 252%, showcasing its robust competitive position and profitability in the market.
- Investment Opportunity Analysis: In the current market environment, UCB and SLM present concerning performance metrics, while NRDS demonstrates strong growth potential, prompting investors to carefully assess the investment value of these stocks.
See More
